Co-Authors
This is a "connection" page, showing publications co-authored by Christopher M. Gomez and Robert Wollmann.
Connection Strength
0.616
-
Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction. J Neurosci. 1997 Jun 01; 17(11):4170-9.
Score: 0.155
-
Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome. J Clin Invest. 2007 Oct; 117(10):2903-12.
Score: 0.079
-
Activation of apoptotic pathways at muscle fiber synapses is circumscribed and reversible in a slow-channel syndrome model. Neurobiol Dis. 2006 Aug; 23(2):462-70.
Score: 0.073
-
Focal caspase activation underlies the endplate myopathy in slow-channel syndrome. Ann Neurol. 2004 Mar; 55(3):347-52.
Score: 0.062
-
Active calcium accumulation underlies severe weakness in a panel of mice with slow-channel syndrome. J Neurosci. 2002 Aug 01; 22(15):6447-57.
Score: 0.055
-
Presynaptic congenital myasthenic syndrome due to quantal release deficiency. Neurology. 2001 Jul 24; 57(2):279-89.
Score: 0.052
-
Genetic manipulation of AChR responses suggests multiple causes of weakness in slow-channel syndrome. Ann N Y Acad Sci. 1998 May 13; 841:167-80.
Score: 0.041
-
Desensitization of mutant acetylcholine receptors in transgenic mice reduces the amplitude of neuromuscular synaptic currents. Synapse. 1997 Dec; 27(4):367-77.
Score: 0.040
-
A transgenic mouse model of the slow-channel syndrome. Muscle Nerve. 1996 Jan; 19(1):79-87.
Score: 0.035
-
Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor. Acta Neuropathol. 1984; 63(2):131-43.
Score: 0.015
-
Effector mechanisms of myasthenic antibodies. Ann N Y Acad Sci. 1993 Jun 21; 681:264-73.
Score: 0.007